PD-L1 assessment in pediatric rhabdomyosarcoma: a pilot study.

about

PD-L1 assessment in pediatric rhabdomyosarcoma: a pilot study.

Item

http://www.wikidata.org/entity/Q55416010

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh

2018年學術文章

@zh-hant

name

PD-L1 assessment in pediatric rhabdomyosarcoma: a pilot study.

@en

PD-L1 assessment in pediatric rhabdomyosarcoma: a pilot study.

@nl

type

Item

label

PD-L1 assessment in pediatric rhabdomyosarcoma: a pilot study.

@en

PD-L1 assessment in pediatric rhabdomyosarcoma: a pilot study.

@nl

prefLabel

PD-L1 assessment in pediatric rhabdomyosarcoma: a pilot study.

@en

PD-L1 assessment in pediatric rhabdomyosarcoma: a pilot study.

@nl

P1476

PD-L1 assessment in pediatric rhabdomyosarcoma: a pilot study

@en

P2093

Cecilia Gardelli

http://www.w3.org/2001/XMLSchema#string

Cinzia Paolino

http://www.w3.org/2001/XMLSchema#string

Giovanni Centonze

http://www.w3.org/2001/XMLSchema#string

Giulia Bertolini

http://www.w3.org/2001/XMLSchema#string

Luca Bergamaschi

http://www.w3.org/2001/XMLSchema#string

Marta Barisella

http://www.w3.org/2001/XMLSchema#string

Massimo Milione

http://www.w3.org/2001/XMLSchema#string

Michela Casanova

http://www.w3.org/2001/XMLSchema#string

Stefano Chiaravalli

http://www.w3.org/2001/XMLSchema#string

P2860

Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer

Nivolumab plus ipilimumab in advanced melanoma.

Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma

PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations

MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer

Nivolumab in previously untreated melanoma without BRAF mutation

Pembrolizumab for the treatment of non-small-cell lung cancer

PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma

Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer

Rhabdomyosarcoma: review of the Children's Oncology Group (COG) Soft-Tissue Sarcoma Committee experience and rationale for current COG studies

P2888

s12885-018-4554-8

P304

652

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/S12885-018-4554-8

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

P577

2018-06-13T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1104557960

http://www.w3.org/2001/XMLSchema#string

P698

29898687

http://www.w3.org/2001/XMLSchema#string

P932

6001160

http://www.w3.org/2001/XMLSchema#string